| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Rachel Rac-Lubashevsky, Heleen A Slagter, Yoav Kessle. Tracking Real-Time Changes in Working Memory Updating and Gating with the Event-Based Eye-Blink Rate. Scientific reports. vol 7. issue 1. 2018-12-14. PMID:28566762. |
these results may support the prefrontal cortex basal ganglia wm model (pbwm) by linking updating and gating to striatal dopaminergic activity. |
2018-12-14 |
2023-08-13 |
Not clear |
| Antonio Pedro Vargas, Francisco Eduardo Costa Cardos. Impulse control and related disorders in Parkinson's disease. Arquivos de neuro-psiquiatria. vol 76. issue 6. 2018-10-11. PMID:29972423. |
the pathophysiology of these disorders seems to be related to abnormal dopaminergic stimulation of the basal regions of the basal ganglia, especially via nigro-mesolimbic pathways. |
2018-10-11 |
2023-08-13 |
Not clear |
| Luigi Trojano, Costanza Papagn. Cognitive and behavioral disorders in Parkinson's disease: an update. II: behavioral disorders. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. vol 39. issue 1. 2018-08-15. PMID:29038946. |
symptoms can be present since early stages of the disease, sometimes even before the appearance of classical motor symptoms, likely in relation to dopamine depletion in basal ganglia and/or to dysfunctions of other neurotrasmitter systems, and others can develop later, in some cases in relation to dopaminergic treatment. |
2018-08-15 |
2023-08-13 |
Not clear |
| Giuseppe Delvecchio, Alessandro Pigoni, Cinzia Perlini, Marco Barillari, Amelia Versace, Mirella Ruggeri, A Carlo Altamura, Marcella Bellani, Paolo Brambill. A diffusion weighted imaging study of basal ganglia in schizophrenia. International journal of psychiatry in clinical practice. vol 22. issue 1. 2018-08-13. PMID:28643537. |
basal ganglia are of particular interest, given not only the high concentration of dopaminergic neurons and receptors, but also for their crucial role in cognitive functions, commonly impaired in schizophrenia. |
2018-08-13 |
2023-08-13 |
Not clear |
| Teresa Mann, Jens Kurth, Alexander Hawlitschka, Jan Stenzel, Tobias Lindner, Stefan Polei, Alexander Hohn, Bernd J Krause, Andreas Wre. [ Molecules (Basel, Switzerland). vol 23. issue 3. 2018-08-13. PMID:29509680. |
the caudate-putamen (cpu), as the main input nucleus of the basal ganglia loop, is fundamentally involved in motor function and directly interacts with the dopaminergic system. |
2018-08-13 |
2023-08-13 |
rat |
| Natàlia Vilor-Tejedor, Alejandro Cáceres, Jesús Pujol, Jordi Sunyer, Juan R Gonzále. Imaging genetics in attention-deficit/hyperactivity disorder and related neurodevelopmental domains: state of the art. Brain imaging and behavior. vol 11. issue 6. 2018-07-09. PMID:27981420. |
we found that ig studies on adhd generally focus on dopaminergic genes and the structure of basal ganglia using structural magnetic resonance imaging (mri). |
2018-07-09 |
2023-08-13 |
Not clear |
| Franziska Wedekind, Angela Oskamp, Markus Lang, Alexander Hawlitschka, Karl Zilles, Andreas Wree, Andreas Baue. Intrastriatal administration of botulinum neurotoxin A normalizes striatal D Journal of neuroscience research. vol 96. issue 1. 2018-06-22. PMID:28695985. |
since the dopaminergic system of the basal ganglia fundamentally contributes to motor function, we investigated the impact of bont-a on striatal dopamine receptor expression using in vitro and in vivo imaging techniques (positron emission tomography and quantitative autoradiography, respectively). |
2018-06-22 |
2023-08-13 |
rat |
| Zoe Woodward, Timothy C R Prickett, Eric A Espiner, Timothy J Anderso. Central and systemic C-type Natriuretic Peptide are both reduced in Parkinson's Disease. Parkinsonism & related disorders. vol 43. 2018-06-12. PMID:28673612. |
c-type natriuretic peptide is a neuropeptide widely expressed in the central nervous system including dopaminergic neurons projecting to basal ganglia. |
2018-06-12 |
2023-08-13 |
human |
| Regina Rumpel, Mesbah Alam, Lisa M Schwarz, Andreas Ratzka, Xingxing Jin, Joachim K Krauss, Claudia Grothe, Kerstin Schwab. Neuronal firing activity in the basal ganglia after striatal transplantation of dopamine neurons in hemiparkinsonian rats. Neuroscience. vol 360. 2018-06-05. PMID:28790019. |
the loss of nigral dopaminergic neurons and the resulting dopamine (da) depletion in the striatum (str) lead to altered neuronal activity and enhanced beta activity in various regions of the basal ganglia (bg) motor loop in patients with parkinson's disease and in rodents in the 6-hydroxydopamine (6-ohda)-lesioned rat model. |
2018-06-05 |
2023-08-13 |
human |
| Agata Budzillo, Alison Duffy, Kimberly E Miller, Adrienne L Fairhall, David J Perke. Dopaminergic modulation of basal ganglia output through coupled excitation-inhibition. Proceedings of the National Academy of Sciences of the United States of America. vol 114. issue 22. 2018-05-15. PMID:28507134. |
dopaminergic modulation of basal ganglia output through coupled excitation-inhibition. |
2018-05-15 |
2023-08-13 |
Not clear |
| Hitomi Aono, Mohammed Emamussalehin Choudhury, Hiromi Higaki, Kazuya Miyanishi, Yuka Kigami, Kohdai Fujita, Jun-Ichi Akiyama, Hisaaki Takahashi, Hajime Yano, Madoka Kubo, Noriko Nishikawa, Masahiro Nomoto, Junya Tanak. Microglia may compensate for dopaminergic neuron loss in experimental Parkinsonism through selective elimination of glutamatergic synapses from the subthalamic nucleus. Glia. vol 65. issue 11. 2018-05-14. PMID:28836295. |
thus, microglia may be involved in a negative feedback loop in the indirect pathway of the basal ganglia to compensate for the loss of dopaminergic neurons in pd brains. |
2018-05-14 |
2023-08-13 |
rat |
| Ahmed Negida, Mohamed Elfil, Attia, Eslam Farahat, Mohamed Gabr, Ahmed Essam, Doaa Attia, Hussein Ahme. Caffeine; the Forgotten Potential for Parkinson's Disease. CNS & neurological disorders drug targets. vol 16. issue 6. 2018-05-11. PMID:27823571. |
parkinson's disease (pd) is the second most common neurological disorder characterized by loss of dopaminergic fibers in the basal ganglia and presence of lewy bodies. |
2018-05-11 |
2023-08-13 |
Not clear |
| Roberta Biundo, Eleonora Fiorenzato, Angelo Antonin. Nonmotor Symptoms and Natural History of Parkinson's Disease: Evidence From Cognitive Dysfunction and Role of Noninvasive Interventions. International review of neurobiology. vol 133. 2018-04-26. PMID:28802926. |
the basal ganglia are implicated in the modulation and integration of sensory information and pain, bladder function is under control of both inhibitory (d1) and facilitatory (d2) dopaminergic inputs, finally reduced dopaminergic activity in the mesocortical and mesolimbic pathways is involved in the development of several nms including mood, motivational, and cognitive alterations. |
2018-04-26 |
2023-08-13 |
Not clear |
| Yudai Takarada, Daichi Nozak. Pupil dilations induced by barely conscious reward goal-priming. Neuropsychologia. vol 103. 2018-04-24. PMID:28733248. |
one possible explanation is that positive stimulus-induced reward signals are processed by the dopaminergic system in the basal ganglia, motivating individuals to increase the effort they invest in particular behaviors, or to recruit the resources necessary for maintaining those behaviors. |
2018-04-24 |
2023-08-13 |
human |
| Sandeep Vasant More, Dong-Kug Cho. Emerging preclinical pharmacological targets for Parkinson's disease. Oncotarget. vol 7. issue 20. 2018-01-12. PMID:26988916. |
parkinson's disease (pd) is a progressive neurological condition caused by the degeneration of dopaminergic neurons in the basal ganglia. |
2018-01-12 |
2023-08-13 |
Not clear |
| Jacob J Crouse, Joseph R Phillips, Marjan Jahanshahi, Ahmed A Moustaf. Postural instability and falls in Parkinson's disease. Reviews in the neurosciences. vol 27. issue 5. 2018-01-02. PMID:26966928. |
the delayed effect of dopaminergic medication combined with the success of extrastriatal deep brain stimulation suggests that pi involves neurotransmitter systems other than dopamine and brain regions extending beyond the basal ganglia, further challenging the traditional view of pd as a predominantly single-system neurodegenerative disease. |
2018-01-02 |
2023-08-13 |
Not clear |
| Joseph R Phillips, Abeer M Eissa, Doaa H Hewedi, Marjan Jahanshahi, Mohamed El-Gamal, Szabolcs Keri, Ahmed A Moustaf. Neural substrates and potential treatments for levodopa-induced dyskinesias in Parkinson's disease. Reviews in the neurosciences. vol 27. issue 7. 2018-01-02. PMID:27362959. |
pd is a neurodegenerative disease, with dopaminergic neuronal loss occurring in the substantia nigra pars compacta, thus disrupting basal ganglia functions. |
2018-01-02 |
2023-08-13 |
Not clear |
| Anna Castrioto, Odeya Marmor, Marc Deffains, Dafna Willner, Eduard Linetsky, Hagai Bergman, Zvi Israel, Renana Eitan, David Arkadi. Anesthesia reduces discharge rates in the human pallidum without changing the discharge rate ratio between pallidal segments. The European journal of neuroscience. vol 44. issue 11. 2017-12-22. PMID:27717186. |
classical rate models of basal ganglia circuitry associate discharge rate of the globus pallidus external and internal segments (gpe, gpi respectively) solely with dopaminergic state and predict an inverse ratio between the discharge rates of the two pallidal segments. |
2017-12-22 |
2023-08-13 |
human |
| Jean-François Daneault, Benoit Carignan, Abbas F Sadikot, Christian Duva. Subthalamic deep brain stimulation and dopaminergic medication in Parkinson's disease: Impact on inter-limb coupling. Neuroscience. vol 335. 2017-12-21. PMID:27514575. |
collectively, the results suggest that structures independent of the dopaminergic system and basal ganglia may mediate temporal and spatial inter-limb coupling. |
2017-12-21 |
2023-08-13 |
Not clear |
| P Medeiros, R L de Freitas, M O Silva, N C Coimbra, L Melo-Thoma. CB1 cannabinoid receptor-mediated anandamide signaling mechanisms of the inferior colliculus modulate the haloperidol-induced catalepsy. Neuroscience. vol 337. 2017-12-21. PMID:27595886. |
there is substantial evidence supporting a role played by the endocannabinoid system as a modulator of the glutamatergic neurotransmission, as well as the dopaminergic activity in the basal nuclei and therefore it may be considered as a potential pharmacological target for the treatment of movement disorders. |
2017-12-21 |
2023-08-13 |
rat |